Last reviewed · How we verify
NCT02124668
A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Phase 2 trial testing Enzalutamide in Castration-Resistant Prostate Cancer in 30 participants. Completed in 25 May 2017.
25 May 2017
Quick facts
| Lead sponsor | Astellas Pharma Europe B.V. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 23 September 2014 |
| Primary completion | 25 May 2017 |
| Estimated completion | 25 May 2017 |
| Sites | 4 locations across Georgia, Russia |
Drugs / interventions tested
- Enzalutamide (enzalutamide) — full drug profile →
Conditions studied
- Castration-Resistant Prostate Cancer — all drugs for Castration-Resistant Prostate Cancer →
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Astellas Pharma Europe B.V. — full company profile →
Who can join
Eligibility, male only, with Castration-Resistant Prostate Cancer or Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to monitor the safety of enzalutamide in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02124668
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Enzalutamide
Trials testing the same drug.
- NCT07287150 — A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer · Phase 2 · recruiting
- NCT07226986 — A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI i · Phase 1, PHASE2 · recruiting
- NCT07277270 — A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tum · Phase 1 · recruiting
- NCT07028853 — This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide W · Phase 3 · recruiting
- NCT06922318 — The COSMYC Trial (COmbined Suppression of MYC) · Phase 2 · recruiting
Other recruiting trials for Castration-Resistant Prostate Cancer
Currently open trials in the same condition.
- NCT04838899 — Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer · NA · recruiting
Other Astellas Pharma Europe B.V. trials
Trials by the same sponsor.
- NCT03702777 — A Study of ASP8302 in Participants With Underactive Bladder · Phase 2 · completed
- NCT04742517 — A Study of MA-0217 (ASP1128) in Healthy Adult Subjects and Healthy Elderly Subjects · Phase 1 · completed
- NCT03282318 — A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Sub · Phase 2 · completed
- NCT03108755 — A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Non-Japanese Adult and Elderly Sub · Phase 1 · completed
- NCT02788123 — A Study To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol) In Combination With Pantoprazole An · Phase 4 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02124668 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Astellas Pharma Europe B.V.
- Last refreshed: 21 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02124668.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing